$12.66 meals Payment -- Biogen to Dr. Eric Sanchez

Biogen provides a $12.66 meal to Internal Medicine physician Eric Sanchez for Spinraza.

This page provides a detailed analysis of a $12.66 meals payment from Biogen to Dr. Eric Sanchez. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$12.66
Payment Typemeals
Payment NatureFood and Beverage
Pharmaceutical CompanyBiogen
PhysicianDr. Eric Sanchez
NPI Number1767530923
Physician SpecialtyInternal Medicine
LocationAthens, GA
Date of Payment2026-03-08
Related Drug/DeviceSpinraza
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Biogen made a $12.66 meals payment to Eric Sanchez, a Internal Medicine specialist in Athens, GA. The payment was associated with Spinraza. Biogen provided a meal valued at $12.66 to Dr. Eric Sanchez on March 8, 2026. The payment was for 'Food and Beverage' related to the drug Spinraza. This represents a small value meal payment, common in pharmaceutical interactions.

Patient Guidance: What This Payment Means for You

This record shows a small meal provided by a pharmaceutical company, which is a common practice and generally does not require specific patient action. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

A $12.66 meal payment is a low-value transaction, typical for routine interactions between pharmaceutical representatives and physicians in Internal Medicine.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

  • biogen
  • eric-sanchez
  • spinraza
  • meals
  • food-and-beverage
  • internal-medicine

Understanding meals Payments

Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.

Frequently Asked Questions About This Payment

What was this $12.66 payment for?

This was a meals payment of $12.66 from Biogen to Eric Sanchez, categorized as "Food and Beverage". It was associated with Spinraza. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Eric Sanchez accept pharmaceutical money?

Yes, Eric Sanchez received this $12.66 payment from Biogen. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Eric Sanchez's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this meals payment?

A meals payment of $12.66 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Internal Medicine?

To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Eric Sanchez's relationship with Biogen?

The payment amount is below typical thresholds for significant influence. This $12.66 meals payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Internal Medicine?

The payment type is 'meals', a common form of interaction.

What should patients do after learning about this payment?

This record shows a small meal provided by a pharmaceutical company, which is a common practice and generally does not require specific patient action.

What else should I know about this meals payment?

The date of payment is in the future (2026), indicating potential pre-reporting or data entry.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.